Please login to the form below

Not currently logged in
Email:
Password:

Pfizer’s Xeljanz picks up a third indication in the US

The JAK inhibitor can now treat patients with ulcerative colitis

XeljanzThe US Food and Drug Administration (FDA) has given its seal of approval to Pfizer’s Xeljanz (tofacitinib), a JAK inhibitor that could strengthen Pfizer’s stance in the inflammatory bowel disease (IBD) market.

The twice-daily, orally administered drug is set to treat adult patients with moderately-severely active ulcerative colitis (UC), an often-debilitating disease that affects approximately 907,000 people in the US alone.

Michael Goettler, global president, inflammation and immunology, Pfizer, said: “Ulcerative colitis is a chronic inflammatory bowel disease that can significantly impact the lives of patients and has limited therapeutic options available.

“With the FDA approval of Xeljanz, adults living with moderately to severely active UC now have an oral option that may help achieve and maintain steroid-free remission.”

The green light was given to Xeljanz based on positive phase III data from the OCTAVE trials, which produced induction data showing a statistically significant, greater proportion of UC patients in remission at week 8 compared to those on placebo.

A similar result presented itself throughout the maintenance study, during which, it was reported that a statistically significant amount of patients were in remission at week 52 compared to those on placebo.

Xeljanz is already doing well in the arthritis disease area - after picking up US approvals in rheumatoid arthritis and psoriatic arthritis - where the drug is the first and only JAK inhibitor approved by the FDA.

Continuing this trend, Xeljanz is also the first and only JAK inhibitor approved in the US to treat UC, and an approval in the IBD therapy area for this particular class of drugs bolsters Pfizer’s position in the market, one that is currently dominated by TNF inhibitors, according to a report by ReportBuyer.

That report also predicted that TNF inhibitors are set to gain more of a market share by the end of 2025, however Xeljanz does have the advantage of being administered orally compared to other FDA-approved treatments for UC, which must be administered through an intravenous infusion or subcutaneous injection.

Article by
Gemma Jones

1st June 2018

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics